Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 146Fluorouracil 137Capecitabine 122Leucovorin 106Irinotecan 85Radiotherapy 67Bevacizumab 64Cetuximab 46Folfox protocol 28Surgical Procedures, Operative 23Radiation 23Drug Therapy 22Panitumumab 19XELOX 18Chemotherapy, Adjuvant 15Neoadjuvant Therapy 14Radiotherapy, Intensity-Modulated 13Chemoradiotherapy 13Magnetic Resonance Spectroscopy 11regorafenib 10Nivolumab 10Floxuridine 10sintilimab 8raltitrexed 8Specimen Handling 8IFL protocol 8Celecoxib 8Biopsy 8trifluridine tipiracil drug combination 7tislelizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Rectal Neoplasms × Clobetasol × Clear all
NCT02368886 2025-06-18

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Completed
123 enrolled 21 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡